New hope for drug-resistant GIST: combo therapy targets stubborn tumors
NCT ID NCT06208748
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new two-drug combination (bezuclastinib plus sunitinib) in 40 adults with advanced gastrointestinal stromal tumors (GIST) that grew while on sunitinib alone. The goal is to see if the combo can slow cancer progression and understand why some tumors resist treatment. Participants must have a specific KIT mutation and be in fair health.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTROINTESTINAL STROMAL TUMORS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Fox Chase Cancer Center
Philadelphia, Pennsylvania, 19111, United States
-
Oregon Health & Science University
Portland, Oregon, 97239, United States
-
Sylvester Comprehensive Cancer Center, University of Miami
Miami, Florida, 33136, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a targeted pill shrink a rare, Treatment-Resistant stomach cancer?
- Massive GIST registry aims to unlock secrets of rare cancer
- Study aims to pinpoint ideal imatinib dose for GIST patients
- New hope for stubborn GIST: experimental drug DCC-2618 enters safety testing
- New drug cocktail targets tough stomach cancer in Last-Resort patients
- New hope for rare stomach cancer: chemo drug shows promise in early trial